TMG (trimethylglycine, betaine) trials recruiting now
7 registrations that name TMG as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 7 registrations
Status
Phase
1US sites across 1 state
1
2 to 4
5 to 19
20 or more
All 7 registrations
RecruitingNCT07144527
Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults
No phase
Scott Silveira
About 40 people
Started Feb 21, 2026
In plain words A study of TMG in people 60 to 80, run by Scott Silveira. It plans to enroll about 40 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 60 to 80; healthy volunteers accepted. Conditions: Aging; Frailty; Exercise Tolerance; Healthy Male and Female Subjects.
Adults aged 60 to 80 years, of any sex
Written clearance from primary care physician confirming medical fitness to participate in an exercise-based clinical study
Normal or near-normal cardiovascular function to safely engage in moderate to vigorous exercise, demonstrated by either: stress echocardiogram or coronary CT angiogram within the past 12 months showing normal left ventricular function, no…
Montreal Cognitive Assessment (MoCA) score of 26 or higher
7 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
NMN and TMG (Euexia); Nicotinamide Mononucleotide (NMN); Placebo
Registered summary
This is a randomized, double-blind, placebo-controlled, two-arm crossover clinical trial evaluating the effects of nicotinamide mononucleotide (NMN) combined with trimethylglycine (TMG) supplementation, compared to NMN alone. The study will assess safety and efficacy in improving exercise tolerance and modulating biomarkers of aging in healthy older adults. The primary outcome is cycle ergometry constant work rate (CWR) exercise tolerance, measured as time to fatigue. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT06264570
Evaluation of a Genetically Determined Personalized Approach in Prescribing Biologically Active Substances in Patients With Elevated Blood Homocysteine Levels.
No phase
S.LAB (SOLOWAYS)
About 111 people
Started Oct 23, 2023
In plain words A study of TMG in people 18 to 80, run by S.LAB (SOLOWAYS). It plans to enroll about 111 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80. Conditions: Hyperhomocysteinemia.
Increased homocysteine level above 15 µmol/l;
Increased LDL level >=1.4 mmol/l.;
Absence of taking medications or any other products that may affect homocysteine levels in the blood for at least 1 month before enrollment in the study;
The clinical trial assesses the effectiveness and safety of a genetically-determined personalized approach to prescribing bioactive substances in patients with elevated blood homocysteine levels. Hyperhomocysteinemia (HHcy) is a risk factor for cardiovascular diseases (CVD), potentially exacerbating the effects of arterial hypertension and high cholesterol levels, increasing the risks of heart disease, stroke, and venous thrombosis. The full summary is on the listing.
Where, as registered
No US site; Russia (1).
RecruitingNCT06881511
Exploratory Study on the Efficacy of Betaine Hydrochloride in Treating Autoimmune Gastritis
No phase
Second Affiliated Hospital, Zhejiang University, School of Medicine
About 100 people
Started Jan 3, 2025
In plain words A study of TMG in people 18 to 80, run by Second Affiliated Hospital, Zhejiang University, School of Medicine. It plans to enroll about 100 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80. Conditions: Autoimmune Gastritis.
Patients diagnosed with autoimmune gastritis at the Second Affiliated Hospital of Zhejiang University School of Medicine, with the diagnostic criteria for autoimmune gastritis based on the article "A real-world study on the characteristics…
Gastrin levels greater than 300 pmol/L or a history of type 1 gastric neuroendocrine tumors or early gastric cancer treated with endoscopic submucosal dissection (ESD);
Age between 18 and 80 years;
Patients who have signed the informed consent form for the clinical trial.
The exclusion criteria are on the listing.
What it tests, as registered
No intervention (Control Group); Oral betaine hydrochloride (2 capsules, 3 times daily)
Registered summary
Autoimmune gastritis (AIG) is a chronic autoimmune disorder characterized by parietal cell destruction and oxyntic mucosal atrophy, leading to achlorhydria and intrinsic factor deficiency. These pathological changes impair iron and vitamin B12 absorption, resulting in iron-deficiency anemia, pernicious anemia, and neuropsychiatric manifestations. Notably, 4-12% of AIG patients develop type 1 gastric neuroendocrine tumors, while facing a 3-7 fold increased risk of gastric adenocarcinoma with an incidence of 0.9-9%. The full summary is on the listing.
Where, as registered
No US site; China (1).
RecruitingNCT06272500
Safety and Efficacy Study of Betaine Hydrochloride in Treating Hypergastrinemia in Patients With Autoimmune Gastritis
No phase
Jianning Yao
About 60 people
Started Jan 1, 2024
In plain words A study of TMG in people of any age, run by Jianning Yao. It plans to enroll about 60 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people of any age. Conditions: Autoimmune Gastritis.
What it tests, as registered
oral administration of receives only oral administration of placebo; oral administration of Betaine hydrochloride
Registered summary
Autoimmune atrophic gastritis (AAG) is an organ-specific autoimmune disease that primarily affects the gastric body and fundus while sparing the antrum. Its characteristics include destruction of gastric wall cells, loss of intrinsic factors, and atrophy of the gastric mucosa. Endoscopic examination reveals features of reverse atrophy, with significant atrophy in the gastric body and fundus, appearing as a mosaic of red and white patches. Currently, AAG is believed to result from a pathological CD4+ T-cell-mediated autoimmune response against the gastric H+/K+-ATPase. The full summary is on the listing.
Where, as registered
No US site; China (1).
RecruitingNCT06308367
The Therapeutic Effect of Betaine in Syringomyelia
Phase 2
Xuanwu Hospital, Beijing
About 30 people
Starts Mar 2024 (estimated)
In plain words A Phase 2 study of TMG in people 18 to 80, run by Xuanwu Hospital, Beijing. It plans to enroll about 30 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80. Conditions: Syringomyelia.
Contraindication to duraplasty and shunting treatment due to history or high risk of severe adverse effects,
non-effective response to duraplasty and shunting treatment in 12 months prior to study entry.
Estimated life expectancy must be greater than 12 months.
Ability to understand and willingness to sign a written informed consent document, or constant caregivers who well understand and willingness to sign a written informed consent document.
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Betaine; Placebo
Registered summary
Purpose: This clinical trial aims to evaluate the indications, therapeutic effects and side effects of betaine in refractory syringomyelia. Primary outcome measure: The primary endpoint is the change of ASIA at week 12. The clinical efficacy is defined as ASIA increase ≥ 1 at week 12, as compared with that before betaine usage.
Where, as registered
No US site; China (1).
Not yet recruitingNCT07276204
Betaine vs. Placebo for Serologically Diagnosed Metabolic Dysfunction-associated Steatohepatitis (MASH)
Phase 2
Southern California Institute for Research and Education
About 70 people
Starts Mar 31, 2026 (estimated)
In plain words A Phase 2 study of TMG in people 18 to 75, run by Southern California Institute for Research and Education. It plans to enroll about 70 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: MASH - Metabolic Dysfunction-Associated Steatohepatitis.
Outpatient
Receiving health care at a clinical site that is participating in this trial.
A clinical diagnosis of metabolic dysfunction-associated steatotic liver disease based in having 1 or more components of the metabolic syndrome.
ALT ≥50 U/L on the most recent measurement and within 28 days prior to randomization
55 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Betaine; Placebo
Registered summary
The study will evaluate whether betaine reduces liver injury in people with metabolic dysfunction-associated steatohepatitis (MASH). MASH is a type of liver disease that occurs in some people with fatty liver. Betaine is a normal component in the human body and will be taken as a pill. Seventy (70) participants will be randomized to receive either betaine or placebo for 24 weeks. After stopping treatment, participants will be seen in clinic for another 24 weeks (total participation in the study is approximately 1 year). The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07840248
Betaine Addition to Water Loading Prior to Running Exercise
No phase
Poznan University of Life Sciences
About 20 people
Starts Oct 1, 2026 (estimated)
In plain words A study of TMG in people 18 to 45, run by Poznan University of Life Sciences. It plans to enroll about 20 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 45; healthy volunteers accepted. Conditions: Exercise; Hydration.
Age 18-45 years
Sex: men and premenopausal women
Continuous running training for at least 12 months
At least 3 running training sessions per week
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Anhydrous Betaine; Placebo
Registered summary
This randomized, double-blind, placebo-controlled crossover study will investigate whether acute betaine ingestion as part of a pre-exercise hyperhydration strategy improves endurance running performance and influences hydration-related responses during prolonged exercise. Approximately 30 recreationally trained male and premenopausal female runners will complete two experimental trials: a betaine condition and a placebo/control condition. The full summary is on the listing.